CAS: 385786-48-1

The HIF prolyl hydroxylase inhibitor is a monoclonal antibody that targets the activity of a protein involved in the regulation of oxygen levels. This protein, HIF prolyl hydroxylase, is responsible for the production of two proteins: erythropoietin and vascular endothelial growth factor (VEGF). The HIF prolyl hydroxylase inhibitor drug results in a cascade of events that leads to an increase in oxygen levels in tissues, preventing hypoxia-induced neuronal death. The HIF prolyl hydroxylase inhibitor has also shown promising results as a treatment for inflammatory bowel disease, which is characterized by increased intestinal permeability. It has been shown to inhibit viral replication and reduce the severity of symptoms related to bowel diseases.

Adaptaquin is an inhibitor of the hypoxia-inducing factor prolyl hydroxylase (HIF-PH) [1] [2].

Adaptaquin